| 02.07.20 |
Connect: Is antibody testing really a passport to Covid freedom? – Metro |
| 24.06.20 |
Open Orphan developing world first challenge study model for Covid-19 vaccines – RTE |
| 24.06.20 |
Open Orphan primed for profitability after transformational year – Proactive Investors |
| 24.06.20 |
Open Orphan develops first challenge study model to test Covid-19 vaccines – The Irish Times |
| 15.06.20 |
Open Orphan sees positive trial on mosquito-borne disesases – The Irish Times |
| 15.06.20 |
Open Orphan study results published in The Lancet
– Independent.ie |
| 12.06.20 |
How a vaccine made of mosquito spit could help stop the next epidemic – The Times of India |
| 08.06.20 |
hVIVO offers coronavirus antibody testing to UK employers – pharmaphorum.com |
| 07.06.20 |
Coronavirus vaccine: wanted — human guinea pigs to be infected with Covid-19 – The Times |
| 06.06.20 |
UP THE ANTI I took the antibody test that could help get millions back to work – by revealing they’ve had Covid WITHOUT realising – The Sun |
| 02.06.20 |
Wanted: People willing to get sick to find Coronavirus vaccine – The Wall Street Journal |
| 26.06.20 |
Inside stories fo Coronavirus battlers Aerogen, Hibergene, Open Orphan and Nearform – The Times |
| 14.05.20 |
Irish companies come out in force to help during COVID-19 pandemic – The Irish Times |
| 11.05.20 |
Open Orphan enters COVID-19 antibody testing partnership – Independent.ie |
| 11.05.20 |
One idea for speeding a Coronavirus vaccine: Deliberately infecting people – The Wall Street Journal |
| 11.05.20 |
Open Orphan. Quotient form COVID-19 antibody testing pact – Shares Magazine |
| 11.05.20 |
Open Orphan’s rapid growth continues with COVID-19 antibody test deal (ORPH) – Value The Markets |
| 11.05.20 |
Open Orphan inks contract with Quotient on COVID-19 antibody testing – ShareCast |
| 23.04.20 |
Open Orphan subsidiary starts testing drug for treating COVID-19 – Independent.ie |
| 23.04.20 |
Dublin-listed Open Orphan to test COVID-19 drug through London subsidiary – The Irish Times |
| 22.04.20 |
Scientists are calling for vaccine experiments that would deliberately infect people with the novel Coronavirus – BuzzFeed News |
| 23.03.20 |
Race to stop the world getting sick: as Coronavirus ravages the globe, experts work round the clock developing vaccines and trialling drugs in desperate attempt to contain it – Mail Online |
| 11.03.20 |
Coronavirus: Inside UK clinic where people get paid up to £4,000 to be infected in race to find vaccine – Mirror |
| 10.03.20 |
Open Orphan joint venture’s flu trial showcased in peer reviewed journal – Proactive Investors |
| 10.03.20 |
Open Orphan positive results from Phase llb field study of FLU-v vaccine – Directors Talk Interviews |
| 09.03.20 |
Open Orphan restarts earlier Coronavirus vaccine efforts – Scrip: Informa Pharma Intelligence |
| 09.03.20 |
Coronavirus: Open Orhan to restart vaccine efforts – The Irish Times |
| 09.03.20 |
People paid £3,500 to be infected with Coronavirus to find cure – Metro |
| 09.03.20 |
Volunteers to be infected with Coronavirus for £3,500 in bid to find vaccine – The Sun |
| 09.03.20 |
Open Orphan PLC joins coronavirus battle – Proactive Investors |
| 09.03.20 |
Irish company to begin Coronavirus vaccine trials – Breaking News.ie |
| 09.03.20 |
Get paid to have Coronavirus: Scientists in London will pay volunteers £3,500 to be infected in experiments to develop vaccine for deadly virus – Mail Online |
| 09.03.20 |
Open Orphan launches world’s first human Coronavirus challenge study – EPM Magazine |
| 09.03.20 |
Open Orhan starts on Coronavirus challenge study model – Morning Star |
| 09.03.20 |
People being offered £3,500 to be infected with Coronavirus in bid to find cure – Birmingham Live |
| 09.03.20 |
Open Orphan’s Cathal Friel on firm’s “milestone” human Coronavirus challenge study (ORPH) – Value The Markets |
| 08.03.20 |
Coronavirus volunteers to be paid £3,500 and infected with form of bug – Daily Star |
| 08.03.20 |
Coronavirus vaccine race: volunteers to be infected in the UK – The Times |
| 08.03.20 |
Volunteers to be infected with Coronavirus for £3,500, in bid to find vaccine – Mirror |
| 06.03.20 |
New hVIVO contract signed with a European Biotech Company – PharmiWeb |
| 27.09.19 |
hVIVO to present at the 2019 European Respiratory Society (ERS) International Congress Madrid |
| 19.09.19 |
Unaudited Interim Results for the Six Months Ended 30 June 2019 |
| 23.08.19 |
Notice of interim results 2019 |
| 06.08.19 |
hVIVO Successfully Completes RSV Challenge Study in Older Adults |
| 31.07.19 |
AGS-v PLUS Phase 1 |
| 31.07.19 |
FD Change July 2019 |
| 17.06.19 |
hVIVO RSV Challenge Model Delivers Positive Results for Novel Therapy |
| 26.04.19 |
2018 Annual Report |
| 11.04.19 |
Preliminary Results for the Year Ended 31 December 2018 |
| 29.03.19 |
hVIVO & Imutex Limited to Present at IVW 2019 |
| 08.03.19 |
Notice of Preliminary Results 2018 |
| 10.01.19 |
Positive Data for Phase IIb FLU-v Challenge Study |
| 31.10.18 |
AGS-v Partial Preliminary Results |
| 08.10.18 |
Two New Contracts for RSV Human Challenge Studies |
| 08.10.18 |
Directorate Change |
| 20.09.18 |
Interim Results |
| 18.06.18 |
hVIVO Reports Positive Results from the Phase IIb Field Study of FLU-v (FLU-v 003) |
| 23.05.18 |
Result of AGM |
| 27.04.18 |
Posting of 2017 Annual Report and Financial Statements |
| 19.04.18 |
Audited 2017 Preliminary Results |
| 19.04.18 |
Chief Executive Officer Steps Down |
| 10.04.18 |
Statement regarding share price |
| 06.04.18 |
Notice of Preliminary Results |
| 26.03.18 |
Initial results from Imutex’s Phase IIb study of FLU-v |
| 30.10.17 |
Directorate Change |
| 21.09.17 |
Half-year Financial Report |
| 20.06.17 |
Board Change |
| 24.05.17 |
Results of AGM |
| 28.04.17 |
Posting of 2016 Annual Report and Financial Statements |
| 20.04.17 |
Audited 2016 Preliminary Results |
| 13.04.17 |
Trading Update |
| 21.02.17 |
hVIVO notes the initiation of a Phase I clinical trial with AGS-v |
| 09.02.17 |
Data from PrEP Biopharm’s two Phase IIa clinical studies |
| 30.12.16 |
Change of auditor |
| 22.09.16 |
Half-year Financial Report |
| 21.09.16 |
Trading update |
| 02.09.16 |
hVIVO Landmark Asthma Study Underway |
| 14.06.16 |
Favourable results for PrEP Biopharm’s Flu Study |
| 24.05.16 |
David Norwood Lock-in Deed |
| 23.05.16 |
Result of AGM |
| 28.04.16 |
Posting of 2015 Annual Report and Financial Statements |
| 25.04.16 |
Initial results for PrEP Biopharm’s PrEP-001 Phase IIa Flu Study |
| 22.04.16 |
Joint Venture Investment with the SEEK Group |
| 20.04.16 |
Board Changes |
| 20.04.16 |
Audited 2015 Preliminary Results |
| 15.12.15 |
Result of General Meeting |
| 26.11.15 |
Conditional Placing to raise £20.5 million |
| 02.11.15 |
hVIVO invests in PrEP Biopharm Limited |
| 02.11.15 |
Trading Update |
| 24.09.15 |
Half Yearly Report |
| 26.05.15 |
Result of AGM |
| 24.04.15 |
Posting of 2014 Annual Report and Financial Statements |
| 16.04.15 |
Audited 2014 Preliminary Results |
| 16.04.15 |
Confirmation of change of name to hVIVO plc |
| 13.04.15 |
Change of Name to hVIVO |
| 16.02.15 |
Trading Update |
| 25.11.14 |
Trading Update |
| 07.10.14 |
Board change |
| 25.09.14 |
Half Yearly Report |
| 01.09.14 |
Result of General Meeting |
| 21.08.14 |
hVIVO HCM of GS-5086 in RSV for Gilead Sciences |
| 14.08.14 |
Conditional Placing to raise £33.6 million |
| 28.07.14 |
hVIVO HCM study of AL-8176 in RSV for Alios BioPharma |
| 14.07.14 |
Board change |
| 26.06.14 |
Board change |
| 12.06.14 |
Board changes |
| 04.06.14 |
Start of hVIVO challenge study in asthma |
| 02.06.14 |
Investor Event |
| 21.05.14 |
Result of AGM |
| 17.04.14 |
Posting of 2013 Annual Report and Accounts |
| 09.04.14 |
Board Changes |
| 09.04.14 |
Audited 2013 Preliminary Results |
| 19.03.14 |
New state of the art biomedical facility in UK |
| 04.03.14 |
Acquisition |
| 16.12.13 |
Trading Update |
| 26.09.13 |
Half Yearly Report |
| 28.08.13 |
Contract Win |
| 23.08.13 |
Contract Win |
| 02.07.13 |
Result of General Meeting |
| 01.07.13 |
Contract Win |
| 14.06.13 |
Conditional Placing to raise £25.5 million |
| 19.04.13 |
Posting of 2012 Annual Report and Accounts |
| 10.04.13 |
Audited 2012 Preliminary Results |
| 07.01.13 |
Contract Win |
| 12.12.12 |
Trading Update |
| 22.10.12 |
Contract Win |
| 24.09.12 |
Half Yearly Report |
| 10.05.12 |
Contract Win |
| 03.05.12 |
First day of Dealings and Admission to AIM |